Free Trial
NASDAQ:HSDT

Helius Medical Technologies Q3 2024 Earnings Report

Helius Medical Technologies logo
$16.24 -0.76 (-4.47%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$16.45 +0.22 (+1.32%)
As of 10/3/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Helius Medical Technologies EPS Results

Actual EPS
-$742.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Helius Medical Technologies Revenue Results

Actual Revenue
$0.05 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Helius Medical Technologies Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Helius Medical Technologies' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Friday, November 14, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Helius Medical Technologies Earnings Headlines

Tilson: “I’m watching HOOD”
A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fastest pace in history. CNBC calls it "the largest wealth creation spree in history." Yet 1 in 3 Americans now fear their financial situation is deteriorating. There's only one way to survive, says the man who predicted 2008 and 2020, but sadly it's already too late for many.tc pixel
See More Helius Medical Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Helius Medical Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Helius Medical Technologies and other key companies, straight to your email.

About Helius Medical Technologies

Helius Medical Technologies (NASDAQ:HSDT) (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics. Frameworks of care vary by region but typically involve coordinated therapy protocols that combine the wearable stimulator, physical exercises and clinician-led monitoring. Helius supports its clinical users with training, device management and remote patient engagement tools to optimize rehabilitation outcomes.

Beyond its core PoNS offering, Helius is advancing an at-home digital therapy program that integrates software-guided exercises and telehealth support. The company collaborates with research institutions and rehabilitation centers to broaden the evidence base for its technology and explore applications in conditions such as mild traumatic brain injury, multiple sclerosis and stroke recovery. Ongoing clinical studies aim to expand indications and refine therapy protocols.

Founded in 2015 and headquartered in Toronto, Ontario, Helius Medical Technologies is led by President and Chief Executive Officer Dan M. Toutant. Since its inception, the company has pursued regulatory clearances across key markets and built partnerships with rehabilitation specialists to bring neuromodulation therapies to patients worldwide.

View Helius Medical Technologies Profile

More Earnings Resources from MarketBeat